[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Summary

Background: Some cancers have high levels of proteins called somatostatin receptors (SSTRs) on the surface of the tumors. These tumors can be in the lung, head and neck, digestive tract, kidneys, and in or near the adrenal glands. Researchers want to know if drug treatments that target SSTRs can help shrink these types of tumors. Objective: To test a study drug ([212Pb]VMT-Alpha-NET) in people with tumors that have SSTRs. Eligibility: People aged 18 years and older with tumors of the lung, kidneys, head and neck, digestive tract, or adrenal glands that have SSTRs.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Sinonasal Neuroendocrine Carcinoma
• Nasopharyngeal Carcinoma
• Esthesioneuroblastoma
• Olfactory Neuroblastoma
• Somatostatin Receptor Positive
• Small Cell Lung Cancers
• Pheochromocytoma/Paragangliomas
• Kidney Cancers
• Head and Neck Tumors
• Gastrointestinal Neuroendocrine Tumors

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 to 120 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

National Cancer Institute (NCI)

Last updated on ClinicalTrials.gov

October 6, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites